Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06121232 · ClinicalTrials.gov registry record · NA
Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study
A NA study of Neuropathy;Peripheral, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06121232 is a NA study of Neuropathy;Peripheral that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 24 participants, below the 40-participant average among 6 other Neuropathy;Peripheral trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06121232, a NA study of Neuropathy;Peripheral, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if a process called neuromodulation can help to improve pain due to CIP
Conditions Studied
Interventions
- OTHER Control Group
- DEVICE Abbott® DRG / Abbott®/Medtronic® SCS
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2026-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06121232
The ClinicalTrials.gov registry entry for NCT06121232 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 40-participant average among 6 other Neuropathy;Peripheral trials with a reported enrollment target (40% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neuropathy;Peripheral appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.
NCT06121232 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06121232 about?
NCT06121232 is a clinical study titled "Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study". To learn if a process called neuromodulation can help to improve pain due to CIP
What is the current status of trial NCT06121232?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2023-11-02. Estimated completion is 2026-04-01.
What conditions does trial NCT06121232 study?
This clinical trial studies the following conditions: Neuropathy;Peripheral.
What interventions are being tested in trial NCT06121232?
The interventions under investigation include: Control Group (OTHER), Abbott® DRG / Abbott®/Medtronic® SCS (DEVICE).
Who is sponsoring clinical trial NCT06121232?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06121232 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuropathy;Peripheral
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain
RECRUITING · NA
-
The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy
ACTIVE NOT RECRUITING · NA
-
Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)
COMPLETED · NA
-
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Exercise and Nutrition Interventions During Chemotherapy K07
COMPLETED · Phase 2
-
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.